Jay Herath/loyno.edu
Mar 24, 2026, 02:50
Jay Herath: Fitusiran Advancing Hemophilia Care Beyond Factor Replacement
Jay Herath, Professor of the Practice at Loyola University, shared a post on LinkedIn:
“Qfitlia (fitusiran), approved in 2025, is a first-in-class siRNA therapy that treats hemophilia A and B by targeting antithrombin-III mRNA in the liver.
Instead of replacing missing clotting factors (Factor VIII or IX), it reduces antithrombin levels, restoring the body’s ability to generate thrombin and form stable blood clots.”
Stay updated with Hemostasis Today.
-
Nov 8, 2026, 19:31Anna Kajaste-Rudnitski: Presenting AAV-Induced p53 Signalling in Human CNS Cells at ESGCT 26
-
Nov 8, 2026, 19:29David McIntosh: Cybersecurity Matters, but Blood Availability Remains the Bigger Challenge
-
Nov 8, 2026, 19:26Wenxue Ma: An Integrative Framework for Macrophage-Mediated Therapeutic Resistance in Cancer
-
Nov 8, 2026, 19:25Yildiz Yigit: Presenting a Polycythemia Vera Case at the MPN Subcommittee Session
-
Nov 8, 2026, 18:56Denis Oduor: Strengthening the Regulation and Delivery of Blood Transfusion and Transplantation Services
-
Nov 8, 2026, 18:28Raghavendra Rao: A Narrative Review on Chronic Venous Disease during Pregnancy
-
Nov 8, 2026, 17:57Dhiren Patel: PLD1-Derived Phospholipids Regulate NAD Kinase and ROS Production in Neutrophils
-
Nov 8, 2026, 17:48Andra T.: What Causes Antiphospholipid Syndrome? – Four Steps, not One Cause
-
Nov 8, 2026, 17:38Nasrin Samadi: Can a Normal Clotting Test Be Misleading?